P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma

• Matthew Mei,
• Joycelynne Palmer,
• Kami Maddocks,
• Peter Martin,
• Ni-Chun Tsai,
• Eileen Smith,
• Leslie Popplewell,
• Saro Armenian,
• Geoffrey Shouse,
• Robert Chen,
• Larry Kwak,
• Steven T. Rosen,
• Stephen Forman,
• David Bond,
• Alex F. Herrera

Affiliations

Matthew Mei

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Joycelynne Palmer

2 Department of Computational and Quantitative Sciences, Beckman Research Institute, City of Hope, Duarte, CA

Kami Maddocks

3 Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Peter Martin

4 Weill Cornell Medicine, New York, NY

Ni-Chun Tsai

2 Department of Computational and Quantitative Sciences, Beckman Research Institute, City of Hope, Duarte, CA

Eileen Smith

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Leslie Popplewell

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Saro Armenian

6 Department of Pediatrics, City of Hope, Duarte, CA

Geoffrey Shouse

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Robert Chen

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Larry Kwak

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Steven T. Rosen

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Stephen Forman

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

David Bond

3 Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Alex F. Herrera

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA